

Leadership Advisory Council Elections


Tier 3



Jon Adkins


XENO THERAPEUTICS

Jon Adkins is a dedicated leader in the development and commercialization of live biotherapeutic products. In 2016, he co-founded XenoTherapeutics and currently serves as its President and board member. Jon and his team have worked tirelessly to build a highly effective clinical-stage, regenerative medicine company developing new biotherapies from genetically engineered animals. Under Mr. Adkins' leadership, the XenoTherapeutics team has successfully translated the first live biotherapeutic skin xenotransplant from theory to therapeutic reality. Today, Jon continues to lead the clinical evaluation of realSKIN® and realNERVE™ while managing the financing and logistical operations that support the research and development efforts at XenoTherapeutics. He has provided a crucial role in the company's regulatory strategy, and expansion of its intellectual property portfolio and led its business development operations with both hospitals and industry partners. With over 20 years of experience in the life sciences industry, Jon is also a co-inventor of 6 patents in xenotransplantation and holds an MBA with an emphasis in healthcare management. Prior to XenoTherapeutics, Jon held multiple roles at top medical device and biotech companies such as Smith & Nephew, Zimmer Biomet, Bacterin (now Xtant Medical), and Johnson & Johnson. He is also a founding member of Alexis Bio, which serves as the commercial arm and partner of XenoTherapeutics Foundation.



Leadership Advisory Council Elections


Tier 3



Jared Auclair

NORTHEASTERN
UNIVERSITY

Jared R. Auclair, PhD is currently the Vice Provost Research Economic Development and Director of Bioinnovation in the Office of the Provost at Northeastern University. As Vice Provost Research Economic Development, Dr. Auclair works to strengthen the bonds between our education and research missions by strengthening the integration of work-integrated credentialed learning and use-inspired research, co-creating with communities and partners while expanding our global mindset. As Director of Bioinnovation, Dr. Auclair works to leverage important University activities around biotechnology, bringing together experts from a wide range of disciplines and backgrounds to advance the expansion of Northeastern life sciences programs. In addition to these roles, Dr. Auclair holds a faculty appointment in the Department of Chemistry and Chemical Biology where he collaborates with academic researchers, industry and government in the area of biopharmaceutical development and analysis.



Leadership Advisory Council Elections


Tier 3



Priya Baraniak

ORGANABIO

Dr. Baraniak is a proven strategic thinker, problem solver and leader who brings 20 years of expertise in stem cells and tissue engineering, coupled with a keen business acumen, to OrganaBio. Dr. Baraniak has published multiple peer-reviewed papers and book chapters on the use of stem cells and biomaterials in cardiac repair and regeneration and is routinely invited to speak at conferences. Before joining OrganaBio, Priya was a founding member of RoosterBio and was a vital member of the company's Leadership Team. At RoosterBio, Priya leveraged her technical expertise to build and rapidly scale the company's sales and marketing engines in a fast-paced start-up environment, delivering impressive growth in revenue year-over-year. Additionally, in her role as Business Development lead at RoosterBio, Priya structured, negotiated and executed multiple strategic partnerships for aggressive growth of the organization. Priya worked with the tech transfer team to transfer cell products and media from process development to cGMP manufacturing at RoosterBio. Priya was also involved in stability program planning and submission of a Drug Master File in support of cGMP products at RoosterBio. Priya's industry experience includes a role as Senior Director of R&D for Garnet BioTherapeutics, a clinical-stage stem cell-based regenerative medicine company, where Priya led multiple projects on tissue repair and regeneration using mesenchymal stem cell (MSC)-based therapeutics and devices. While at Garnet Bio, Priya also worked on the company's FDA filings, contributed to drafting and prosecuting the company's patent portfolio, managed CRO, CMO and industry partner relationships and actively participated in establishing Garnet's strategic R&D plan, thereby gaining critical insights into business operations across a small organization.



Leadership Advisory Council Elections


Tier 3



**Harihara
Baskaran**

CASE WESTERN
RESERVE UNIVERSITY

Dr. Baskaran is a biomedical engineer with a chemical engineering background. He obtained his PhD in Chemical Engineering at Penn State and subsequently did post-doctoral research in Biomedical Engineering at Shriners Hospitals for Children, Massachusetts General Hospital and Harvard University. He is currently a Professor and the Chair of Chemical and Biomolecular Engineering at CWRU. He has over two decades of research experience in biotransport applications. He has worked on many biomedical applications including intravascular lung development, extracorporeal wearable oxygenators, extracorporeal liver devices, microvascular tissue engineering, and cartilage tissue engineering.



Leadership Advisory Council Elections


Tier 3



Didarul Bhuiyan

WEST PHARMACEUTICALS

Dr. Didarul B. Bhuiyan is a Sr. Biomedical Engineer at West Pharmaceuticals R&D. His current research focus is to enable clinical transition of bioprinting workflow through containment, storage and transportation solutions and devices for bioink and Tissue Engineered Medical Products (TEMPs). Previously, he worked as an R&D scientist at MilliporeSigma and was responsible for developing TissueFab™ bioink formulation products for globally leading life science product portfolio Sigma Aldrich. Dr. Bhuiyan completed his PhD in Biomedical Engineering from University of Alabama at Birmingham and post-doctoral fellowship at University of Minnesota with extensive research focus on bioprinting and tissue engineering. He has published a dozen peer reviewed research articles and was awarded two patents in the field of bioinks.



Leadership Advisory Council Elections


Tier 3



Marcie Black

ADVANCED SILICON GROUP

Marcie Black is CEO and co-founder of Advanced Silicon Group. Dr. Black brings to the company expertise in building strong teams, managing development projects, patents, IP strategy, encouraging a healthy company culture, cost modeling, and running a startup. In addition, Dr. Black has a strong technical background in the areas of electronic materials, optics, semiconductors, solar cells/photovoltaics, batteries, renewable energy, nanotechnology, device design, and opto-electronics. Prior to founding ASG, Marcie was the President and co-founder of Bandgap Engineering, which focused on lowering the cost of solar electricity through black silicon or silicon nanowire solar cells. Before joining Bandgap, Marcie was a technical staff member at Los Alamos National Laboratory and worked on a variety of nanotechnology and optical systems. She began at Los Alamos National Labs as a prestigious Director's Funded Post Doc, developing organic and nano solar cells. Marcie has a Ph.D. from MIT in Electrical Engineering, under the supervision of Institute Professor, Mildred Dresselhaus. Prior to her Ph.D. work, Marcie was a device engineer at Motorola where she was on a small team responsible for combining non-volatile memory and logic onto the same chip. She improved the manufacturing yields by working with the process engineer to improve silicide formation. In 2009, she was awarded an R&D 100 award for her contributions to work at LANL. Marcie also was honored as one of the ten "Women-to-Watch in 2010" by Mass High Tech. Marcie has over 30+ papers and more than 15 issued patents with many more pending.



Leadership Advisory Council Elections


Tier 3



Don Brezinski

SOUTHERN NEW
HAMPSHIRE UNIVERSITY

Don possesses nearly 20 years of senior level management experience in higher education in the areas of career development, fund raising and alumni relations, grants, and corporate relations. His current responsibilities as SNHU's Chief Campus Administrator entail the developing and implementing a long-term strategy for the SNHU campus that aligns with the goals of the larger University, while leading the daily aspects of the campus that include faculty relations; new program development; student affairs; finance and operations; facilities; enrollment; and corporate outreach.



Leadership Advisory Council Elections


Tier 3



Mark Cohen

UNIVERSITY OF
ILLINOIS

Mark Cohen, MD, FSSO, FACS is the Dean of the Carle Illinois College of Medicine and Senior Vice President and Chief Academic Officer for Carle Health. He is a practicing surgical oncologist and endocrine surgeon and a tenured professor of Surgery and Biomedical and Translational Sciences in the College of Medicine and The Founder Professor in the Grainger School of Engineering in the Department of Bioengineering. His research covers several areas including novel approaches to tissue engineering to create functional organs from fat stem cells; creation of a novel class of anticancer drug compounds that target chaperone proteins; nanoparticle drug-delivery systems for cancer and bone regeneration; and use of mixed reality and AI/ML technologies to improve telemedicine, clinical care delivery as well as health care workforce training and education. He has been continuously funded by the NCI (NIH) for 17 years and his work has also been funded by the National Science Foundation, the Komen Foundation, the American Cancer Society, the Department of Defense, and even NASA. He has published over 140 peer reviewed manuscripts and has held multiple leadership roles in national and international medical and surgical societies and is a founding member of the international holomedicine association. For his work in mixed reality applications in medical education he was awarded the 2019 Distinguished Faculty Award for Innovation and the 2021 Provost Award for Innovation in Education at the University of Michigan. He is also a serial entrepreneur founding 5 companies in the digital health, medical device, and medical therapeutics sectors and has mentored over 350 students and faculty on innovation projects and startups. He also managed a small internal venture fund focused on surgical innovation and is the author of a textbook on Surgical Innovation in Academic Medicine published through Springer-Nature.



Leadership Advisory Council Elections


Tier 3



**Selen
Cremaschi**

AUBURN UNIVERSITY

Dr. Cremaschi is the Chair, B. Redd & Susan W. Redd Endowed Eminent Scholar Chair Professor, and Head of the Cremaschi group in the Department of Chemical Engineering, Auburn University. Her research focuses on risk management, optimization, process synthesis, machine learning, and planning under uncertainty. Her research group develops systems analysis and decision support tools for complex systems, mainly focusing on the biomanufacturing, pharmaceutical, and energy industries. She is a recipient of the NSF CAREER award (2011), the Zelimir Schmidt Award for Outstanding Researcher (2013), and the Senior Research Award for Excellence (2021), among others. She is a member of the 2018 Class of Influential Researchers selected by the Industrial and Engineering Chemistry Research journal. She serves on the Digital Technology Advisory Board of The Dow Chemical Company. Her research work has been consistently supported by industrial collaborations in addition to federal agencies. She earned a Ph.D. from Purdue University and an M.S. and B.S. from Bogazici University (Turkey), all in chemical engineering.



Leadership Advisory Council Elections


Tier 3



Marie Csete

OKULOVISION

Marie Csete MD, PhD is the CEO and Founder of OkuloVision, with previous industry experience as the Executive VP for R&D at Organovo, CMO of Avicena, and President/CEO of the nonprofit Huntington Medical Research Institutes. Dr. Csete was the first CSO of CIRM, California's state stem cell agency. As a medical school professor she led transplant anesthesiology services at UCSF, UCLA, Michigan, and Emory, and served as co-director of the Emory/Georgia Tech MD/PhD program. Her lab studied how stem cells age. Dr. Csete was educated at Princeton (AB, Music), Columbia (MD) and Caltech (PhD) where she was awarded Caltech's highest honor to a student, the Clauser Prize. Her PhD work was important for translation of many stem cell products, including OkuloVision's cone progenitor cells. Dr. Csete is a volunteer with the Medical Reserve Corps of Los Angeles, and serves on several for-profit and non-profit boards including the Pasadena Bio Collaborative Incubator.



Leadership Advisory Council Elections


Tier 3



Paul Goodwin

CYTIVA

Paul Goodwin is the Science Director for Cytiva and resides in Seattle, WA. He studied Biology at the University of California, San Diego and Physiology and Biophysics at the University of Washington, Seattle. He created and managed the Image Analysis Laboratory at the Fred Hutchinson Cancer Research Center in Seattle prior to joining Applied Precision where he acted as the CSO prior to its acquisition by GE Healthcare and now Cytiva, a Danaher Life Sciences company. He is the inventor of thirteen patents and numerous peer-reviewed scientific papers and book chapters. He helped to teach microscopy courses at the Marine Biological Laboratory (MBL) in Woods Hole, MA for over 20 years. He is the Past President of The Histochemical Society and Co-Director of Immunohistochemistry and Immunofluorescence (IHCIF), a hand-on workshop sponsored by the Society. He has served on several advisory councils including the Leadership Advisory Council for the Advanced Regenerative Manufacturing Institute in 2020 and 2022. He is the Co-Director of the upcoming Gordon Research Conference titled “Advanced Cell and Tissue Biomanufacturing” (along with Dr. Kaiming Ye) in June of 2023. As the Science Director for Cytiva, Paul’s role is to explore the future of science, technology, and business models that will affect Life Sciences and investigate ways to convert challenges into business opportunities. In addition, he helps drive innovation processes within Cytiva, Pall Biotechnology, and other Danaher operating companies.



Leadership Advisory Council Elections


Tier 3



Brian Hawkins

PLURISTYX

Dr. Brian Hawkins received his Doctorate in Molecular Cell Biology and Biotechnology from the Virginia Polytechnic Institute and State University. He is an internationally recognized expert in cell metabolism and cryopreservation with over 15 years of combined experience in academic and industrial research. He formerly served as a founding member and assistant professor in the Mitochondria and Metabolism Center at the University of Washington before transitioning to cell therapy as Scientific Applications Director at BioLife Solutions, and ultimately as the Chief Technology Officer for Pluristyx. He serves on numerous national committees that aim to advance the development and manufacture of cell therapy and regenerative medicine products and was team leader for the upcoming PDA/ANSI Cryopreservation Standard. Dr. Hawkins is an active member of ARMI and has served on the Leadership Advisory Council previously.



Leadership Advisory Council Elections


Tier 3



Ming-I Huang

ARACARI BIOSCIENCES

Ming-I Huang is Aracari's Chief Executive Officer. She is also the Chief Financial Officer of Aracari since its founding. She has over 40 years of experience in finance, actuarial science, business development, and quantitative risk analysis and served on the senior finance and risk management teams of several publicly-traded insurance groups including American International Group, QBE and Hannover Reinsurance. Ms. Huang received her M.A. degree in Mathematical Statistics from University of Massachusetts at Amherst.



Leadership Advisory Council Elections


Tier 3



Tom Lowery

SATELLITE BIO

Dr. Thomas Lowery joined Satellite Bio in August of 2020 as Chief Technology Officer. Lowery is an experienced scientist, entrepreneur and executive. He brings 15 years of deep experience in product, process and analytical development and engineering as well as building highly productive technical and operational teams. Lowery has led technology innovation from inception through FDA to commercialization and clinical use for seven products that are currently in use in U.S. and international hospitals. Prior to Satellite, Lowery was the Chief Scientific Officer at T2 Biosystems. He joined T2 as the first employee in February 2007, and built and led the technical teams from company launch through IPO and regulatory approval to worldwide commercialization. He has extensive experience in building, scaling and leading teams, product and test development in a regulated environment, developing manufacturing processes, working with regulatory agencies on first-in-class products, developing an intellectual property portfolio, completing multi-center clinical studies, and private, public and non-dilutive fundraising. Lowery's scientific achievements include 40 issued patents, 23 published patent applications, and 42 published peer-reviewed articles or book chapters. His publications span a diverse set of journals including Science, Clinical Chemistry, Protein Science, Blood, Science Translational Medicine, PNAS and Journal of the American Chemical Society. Lowery earned his PhD in Biophysical Chemistry from the University of California, Berkeley and graduated Summa Cum Laude with a BS in Biochemistry and University Honors from Brigham Young University.



Leadership Advisory Council Elections


Tier 3



David Mann

VASCUGEN

David Mann's experience begins in 2002 at Infinity Pharmaceuticals, where he worked as an Associate Director for 10 years, where he became the global sourcing manager for the phytochemical cyclopamine. In 2013, David joined Cellular Dynamics International as a Product Manager for iPSC-Derived Tissues. David was later promoted to Global Business Director for Drug Discovery and Bioengineering, where he established revenue-generating and collaborative research projects with industry researchers. In 2018, David founded MTB Consultants Worldwide LLC to leverage his diverse experience in drug discovery and stem cell sciences. At MTB, he worked with small and mid-sized companies to define strategic directions in science and business. Currently, David is the Chief Executive Officer of Vascugen. Prior to this, he held the position of General Manager at Vascugen. David Mann completed his Bachelor of Science (BS) degree in Chemistry and Cellular & Molecular Biology at the University of Michigan from 1987 to 1991. David then went on to pursue a PhD in Organic Chemistry at the University of Wisconsin-Madison from 1994 to 2000.



Leadership Advisory Council Elections


Tier 3



Doug McConnell


SAFI BIOTHERAPEUTICS

As co-founder and CEO of Safi Biotherapeutics, Mr. McConnell launched and scaled-up the pre-clinical stage cell therapy company to biomanufacture blood cells from allogeneic human hematopoietic progenitor sources via novel and proprietary cell differentiation and expansion techniques. Safi Biotherapeutic's mission is to produce allogeneic blood cells on-demand, at multi-unit transfusion volumes and viable economics where alternatives to donor blood supply are needed. As CEO, Doug is responsible for setting strategic vision, leading portfolio rationalization and prioritization, and establishing the company culture. Prior to Safi, Doug held strategic and operational leadership positions at Vertex Pharmaceuticals and Radius Health that spanned the functional areas of research operations, pre-clinical development, clinical development, regulatory, quality assurance, integrated program management, and commercial launch operations. As part of these biopharmaceutical company roles Mr. McConnell participated on drug development teams responsible for 3 NDA submissions and approvals. In the early phase of his career, he worked in management consulting leading strategic initiatives within major biopharmaceutical companies, as well as other industries such as magazine publishing, music production, and paper manufacturing. Doug obtained his master's in business administration from MIT Sloan, and his bachelor's degrees in business and computer science from Rensselaer Polytechnic Institute.



Leadership Advisory Council Elections


Tier 3



Amy Peterson

UNIVERSITY OF
MASSACHUSETTS, LOWELL

Amy Peterson is an Associate Professor of Plastics Engineering at University of Massachusetts Lowell with expertise in interfacial phenomena and additive manufacturing (AM). Her research group studies processing-structure-property relationships in polymers and polymer composites, with a focus on interfacial phenomena in multilayered systems. She received her PhD in 2011 from Drexel University. She was an Alexander von Humboldt Postdoctoral Fellow while at the Max Planck Institute of Colloids and Interfaces 2011-2013 and was an Assistant Professor of Chemical Engineering at Worcester Polytechnic Institute 2013-2018. Ongoing projects include tailoring of interfacial interactions to facilitate flow and AM of highly loaded composites, real-time control of and property prediction for AM, and coatings for cell culture surfaces capable of controlled release for cell manufacturing. She has served on the ARMI BioFabUSA LAC since 2019.



Leadership Advisory Council Elections


Tier 3



Mark Powers

THERMO FISHER
SCIENTIFIC

Mark Powers has been focused on the innovation and commercialization of cell-based tools, reagents, and systems for over 20 years. He currently serves as Vice President of R&D for Cell Biology, Cell Culture and Cell Therapy at Thermo Fisher Scientific, overseeing the development of novel products and technologies related to the generation, culture, engineering, processing and analysis of diverse cell systems. Prior to his current role, Mark was actively involved in research initiatives directed towards tissue engineering and the creation of physiologically relevant primary and stem cell model systems for use in research, drug discovery and cell therapy. He received a B.S. in Chemical Engineering from Northwestern University; a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology; and completed postdoctoral appointments in Surgical Research at Harvard Medical School and Biological Engineering at the Massachusetts Institute of Technology.




Leadership Advisory Council Elections

Tier 3



Janna Register
MINUTIA

Dr. Janna Register has a passion is translating photonics and non-invasive optical sensing into real-world applications to push the boundaries of when, where, and how we get data. As VP of Engineering at Minutia, she leads a team of nanoparticle chemists and engineers focused on delivering gold-based nanosensors deployed inside stem cell-derived insulin producing cells to track cell health post-transplantation and the non-invasive optical systems used after transplantation to monitor the health of the cell therapy graft in vivo. Prior to Minutia, Dr. Register spent 6 years in industry working in various R&D leadership roles. She worked at a Series C startup focused on bringing to market wearable, wireless body chemistry monitoring devices. She was responsible for bringing wireless, optical continuous glucose monitors through the design control process to clinical readiness. Dr. Register successfully led the in-house build, characterization, release and shipment of wearable readers in support of three clinical trials in Europe and Asia. She also finalized the design of a wearable, optical reader for tissue oxygen monitoring, led the engineering effort for CE mark submission on the product, and successfully completed design transfer to commercial production of the wearable medical device for tissue oxygen monitoring. Dr. Register spent 3 years working at the North American R&D Center for a global industrial gas company, where she focused on developing capabilities to use optical sensors for in-line process analysis and control of product streams in Biogas plants and Electronics Specialty Gases products. While there, she set up a spectroscopy lab, became certified as a Laser Safety Officer for the site, and worked on many other projects utilizing her broad background in analytical chemistry. Dr. Register earned a Ph.D. in Physical Chemistry at USC with a concentration in Applied Spectroscopy. Specifically, she spent years gaining experience in the design, management, upkeep, and operation of lasers and optical system for sensing in real-world applications. After her Ph.D., she spent 3 years in the lab of Tuan Vo-Dinh at Duke University as a postdoctoral fellow and later research scientist. At Duke, she homed her abilities to lead and organize a cross-functional group of scientists by serving as technical project manager for a DARPA project that included multiple research groups at Duke and in industry.



Leadership Advisory Council Elections


Tier 3



Eric Schuur

HEPATX

Eric Schuur has extensive experience as an entrepreneur, scientist, and consultant in the biopharma and medical device industries. He has lead teams taking ideas to the clinic and on to marketing approval. He has abundant start up and emerging company experience with many early-stage companies, including Calydon, Inc. and Asthmatx, Inc. At Calydon Eric lead the team developing one of the first oncolytic viruses targeting a variety of cancers, a program that was ultimately bought by CellGenesys. At Asthmatx, Eric was a key clinical team member bringing the company's asthma product from its pilot feasibility studies in humans to its pivotal trial, resulting in approval of a PMA for the product, leading to acquisition of the company by Boston Scientific. As a consultant, Eric helped molecular diagnostic companies, including Genomic Health and Janssen Diagnostics to market their tests to physician customers by helping to design and execute post-market studies to support reimbursement decisions and customer outreach. At Hepatx, Eric has built the team and lead licensing, tech transfer, confirmation of proof of concept, and development of commercialization plans for SF-Heps, a celltherapy for liver disease. His interests and expertise include regenerative medicine, gene therapy, diagnostics, and oncology. He is passionate about medical innovation and entrepreneurship. In addition to building new companies, Dr. Schuur supports translational research and entrepreneurship education at Stanford University: he serves as a Mentor to the Office of Technology Licensing Innovation Farm Team program and an Adviser to the School of Medicine SPARK program. He received his Ph.D. degree in Experimental Pathology from the UCLA School of Medicine.



Leadership Advisory Council Elections


Tier 3



Ramille Shah

DIMENSION INX

Ramille Shah is the Co-founder, Head of R&D and Chief Science Officer at Dimension Inx. She is driven to develop and translate new innovative biomaterials and devices that can make a significant impact in healthcare and enhance patient quality of life. With over 20 years of experience in biomaterials and tissue engineering, she has established herself as a renowned leader in materials development for 3D-printing. Dimension Inx spun out of her lab at Northwestern University, where she spent the first nine years of her academic career as an Assistant Professor in the Departments of Materials Science and Engineering and Surgery. In addition to her role at Dimension Inx, she is a tenured Associate Professor in Bioengineering at the University of Illinois at Chicago. Ramille earned her B.S. in Materials Science and Engineering (MSE) at Northwestern University and her Ph.D. in MSE with a specialty in Biomaterials from the Massachusetts Institute of Technology.



Leadership Advisory Council Elections

Tier 3



Sandy Williams

ACCESS BIOMEDICAL
SOLUTIONS

Sandy Williams, Ph.D., is a biomedical engineer, marketer, Certified Social Media Strategist, and President of Access Biomedical Solutions, a consultancy focused on empowering biotech and medtech companies grow and accomplish their goals. Sandy's background and expertise offer a unique perspective that she can bring to the LAC to represent the interests of ARMI members. Sandy is a biomedical engineering expert focused on regenerative medicine. She completed her Ph.D. in Biomedical Engineering in 2003 from the Georgia Institute of Technology, where she focused on the development of bioreactors for small diameter tissue-engineered vascular grafts. She continued her postdoctoral training at the University of Minnesota in heart valve and vascular graft tissue engineering and then spent 10 years in industry in various roles as an applications engineer, market manager for tissue engineering and biomaterials, biologics business unit manager and director of market/product vision development and customer satisfaction. Sandy has authored several papers in peer-reviewed journals, is co-inventor on multiple tissue engineering bioreactor and medical device patents, has presented at numerous international conferences and is very actively engaged in volunteer professional activities in the biomedical field. She has chaired two ASTM standard guides on the characterization of tissue engineered vascular grafts and heart valves, is an invited reviewer of submitted manuscripts to the Annals of Biomedical Engineering, Tissue Engineering journals and Cellular and Molecular Bioengineering, has served as a program evaluator for biomedical engineering programs for ABET, and is an SBIR/STTR grant reviewer for NSF.

